Drugs / KSP/QRH dimer
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04304781 | Sep 2020 → Dec 2021 | cholangiocarcinoma | Danielle Kim Turgeon | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KSP/QRH dimer | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04304781 ↗ |
| Modality | Peptide | “fluorescent-labeled peptide dimer” NCT04304781 ↗ |
| Route | Topical | “topical application of a peptide dimer” NCT04304781 ↗ |
| Target | EGFR | “QRH binds specifically to Epidermal Growth Factor Receptor (EGFR)” NCT04304781 ↗ |
| Target | HER2 | “KSP binds specifically to Human Epithelial Growth Factor Receptor (HER2)” NCT04304781 ↗ |